Amgen, Inc. (AMGN) Stock Recommendation | Score, Valuation, Technicals & Financial Trend

Score

Click here to find our call on this stock

Strong Sell

Sell

Hold

Buy

Strong Buy

Comparison

Company

Score

Quality

Valuation

Financial

Technical

Amgen, Inc.

Gilead Sciences, Inc.

Halozyme Therapeutics, Inc.

Bio-Techne Corp.

Elanco Animal Health, Inc.

Illumina, Inc.

Biogen, Inc.

BioMarin Pharmaceutical, Inc.

Moderna, Inc.

Vaxcyte, Inc.

Immunovant, Inc.

Why is Amgen, Inc. ?

High Management Efficiency with a high ROCE of 22.31%

With a growth in Net Profit of 65.85%, the company declared Very Positive results in Jun 26

OPERATING CASH FLOW(Y) Highest at USD 12,478 MM
DEBT-EQUITY RATIO (HY) Lowest at 370.59 %
DIVIDEND PER SHARE(HY) Highest at USD 4.04

With ROCE of 18.91%, it has a fair valuation with a 4.30 Enterprise value to Capital Employed

The stock is trading at a discount compared to its peers' average historical valuations
Over the past year, while the stock has generated a return of 44.34%, its profits have risen by 62.9% ; the PEG ratio of the company is 0.3

High Institutional Holdings at 91.84%

These investors have better capability and resources to analyse fundamentals of companies than most retail investors.
Their stake has increased by 8.69% over the previous quarter.

Market Beating Performance

The stock has generated a return of 44.34% in the last 1 year, much higher than market (S&P 500) returns of 22.36%

Real-Time Research Report

Verdict Report

How much should you hold?

Overall Portfolio exposure to Amgen, Inc. should be less than 10%
Overall Portfolio exposure to Pharmaceuticals & Biotechnology should be less than 30%

(If sector exposure > 30%, please use optimiser tool to see which are the best stocks to hold in Pharmaceuticals & Biotechnology)

When to exit? - We will constantly monitor the company and suggest at the appropriate time to exit from the stock

Is Amgen, Inc. for you?

Medium Risk, High Return

Absolute

Risk Adjusted

Volatility

Amgen, Inc.

44.34%

1.27

27.50%

S&P 500

22.36%

1.70

13.18%

Quality

Management Risk

Growth

Capital Structure

Quality grade scale :

Below Average, Average, Good, Excellent

Quality key factors

Factor

Value

Sales Growth (5y)

7.79%

EBIT Growth (5y)

2.75%

EBIT to Interest (avg)

4.81

Debt to EBITDA (avg)

2.91

Net Debt to Equity (avg)

7.83

Sales to Capital Employed (avg)

0.49

Tax Ratio

10.78%

Dividend Payout Ratio

66.92%

Pledged Shares

Institutional Holding

83.15%

ROCE (avg)

22.31%

ROE (avg)

234.10%

Valuation

Valuation Scorecard

Valuation grade scale :

Very Risky, Risky, Very Expensive, Expensive, Fair, Attractive, Very Attractive

Valuation Key Factors

Factor

Value

P/E Ratio

Industry P/E

Price to Book Value

21.72

EV to EBIT

22.77

EV to EBITDA

15.14

EV to Capital Employed

4.30

EV to Sales

6.36

PEG Ratio

0.34

Dividend Yield

2.04%

ROCE (Latest)

18.91%

ROE (Latest)

100.80%

Technicals

Technical key factors

Indicator

Weekly

Monthly

MACD

Mildly Bearish

Bullish

RSI

No Signal

Bollinger Bands

Mildly Bullish

Moving Averages

Mildly Bullish (Daily)

KST

Mildly Bearish

Bullish

Dow Theory

No Trend

Bullish

OBV

Mildly Bearish

No Trend

Technical Indicator Scale: Bearish, Mildly Bearish, Sideways, Mildly Bullish, Bullish Turned

Technical Movement

Analyse All Technical Factors

Financial Trend

Financial Trend Scorecard

Financial Trend scale:

Very Negative, Negative, Flat, Positive, Very Positive, Outstanding

11What is working for the Company

OPERATING CASH FLOW(Y)

Highest at USD 12,478 MM

DEBT-EQUITY RATIO (HY)

Lowest at 370.59 %

DIVIDEND PER SHARE(HY)

Highest at USD 4.04

RAW MATERIAL COST(Y)

Fallen by -7.45% (YoY

NET SALES(Q)

Highest at USD 10,067 MM

PRE-TAX PROFIT(Q)

At USD 2,756 MM has Grown at 77.35%

NET PROFIT(Q)

At USD 2,364.7 MM has Grown at 66.62%

-2What is not working for the Company

DIVIDEND PAYOUT RATIO(Y)

Lowest at 57.72%

DEBTORS TURNOVER RATIO(HY)

Lowest at 4.04 times

Here's what is working for Amgen, Inc.

Operating Cash Flow

Highest at USD 12,478 MM and Grown

In each year in the last three years

MOJO Watch

The company has generated higher cash revenues from business operations

Operating Cash Flows (USD MM)

Debt-Equity Ratio

Lowest at 370.59 % and Grown

In each half year in the last five Semi-Annual periods

MOJO Watch

The company has been reducing its borrowing as compared to equity capital

Debt-Equity Ratio

Dividend per share

Highest at USD 4.04 and Grown

In each year in the last five years

MOJO Watch

Company is distributing higher dividend from profits generated

DPS (USD)

Net Sales

Highest at USD 10,067 MM

in the last five periods

MOJO Watch

Near term sales trend is positive

Net Sales (USD MM)

Pre-Tax Profit

At USD 2,756 MM has Grown at 77.35%

Year on Year (YoY)

MOJO Watch

Near term Pre-Tax Profit trend is positive

Pre-Tax Profit (USD MM)

Net Profit

At USD 2,364.7 MM has Grown at 66.62%

Year on Year (YoY)

MOJO Watch

Near term Net Profit trend is positive

Net Profit (USD MM)

Raw Material Cost

Fallen by -7.45% (YoY)

MOJO Watch

The company's ability to pass on the cost of raw materials to customers has improved; this may lead to a rise in profit margin

Raw Material Cost as a percentage of Sales

Here's what is not working for Amgen, Inc.

Debtors Turnover Ratio

Lowest at 4.04 times

in the last five Semi-Annual periods

MOJO Watch

Company's pace of selling Debtors has slowed

Debtors Turnover Ratio

Dividend Payout Ratio

Lowest at 57.72%

in the last five years

MOJO Watch

Company is distributing lower proportion of profits generated as dividend

DPR (%)